List of Wynzora drug patents

Wynzora is owned by Mc2.

Wynzora contains Betamethasone Dipropionate; Calcipotriene.

Wynzora has a total of 1 drug patent out of which 0 drug patents have expired.

Wynzora was authorised for market use on 20 July, 2020.

Wynzora is available in cream;topical dosage forms.

The generics of Wynzora are possible to be released after 27 September, 2027.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10265265 MC2 Topical composition
Sep, 2027

(4 years from now)

Exclusivity Exclusivity Expiration
New Dosage Form (NDF) Jul 20, 2023

Drugs and Companies using BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE ingredient

Market Authorisation Date: 20 July, 2020

Treatment: NA

Dosage: CREAM;TOPICAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in